Файловый архив студентов. Файловый архив студентов.
1327 вузов, 5482 предметов.
/ Регистрация
FAQ Обратная связь Вопросы и предложения
Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Ростовский Государственный Медицинский Университет
Предмет:
Медицина общая
Файл:
Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5608_Библиотеки_им_академика_М_И_Перельмана.pdf
Скачиваний:
0
Добавлен:
02.09.2026
Размер:
21 Мб
Скачать
☆
►Содержание►
250
Table 9.4 Opportunities for further innovation
Challenge Potential solutions
High operation costs Adopt innovative curriculum and interdisciplinary learning
approaches to train highly skilled workforce to meet the highly technical nature of the development and manufacturing process [103] Allogeneic, “off the shelf” therapies reduce the number of batches per patient [97]
Long vein-to-vein time Decentralized manufacturing [97, 102]
Adopt manufacturing platforms to reduce cell expansion time by increasing T-cell stemness [71, 72]
Treating solid tumors CAR NK cells, CAR macrophages, gene editing [53]
Polyclonal T-cells with enhanced stemness [73]
Improve efciency, optimizing workows
Utilizing allogeneic or iPSC-derived CAR-T cells
Potential immunotoxicity Develop highly specic antigens [104]
Cold supply chains across international borders
Automated lling and closed systems [98]
Gene editing (CRISPR, TALENs) to overcome immune rejection [99, 100].
Develop CAR “switch-offs” including apoptosis inducers and CAR anti-bodies [105, 106]
Innovative supply chain considerations [86]
A. Adeniran et al.
vector production, should have a positive impact in increasing affordability of CAR-T products. Proposed strategies for optimizing production workows are out­lined in Table9.5.
Use of molecular gene editing techniques like CRISPR or TALENs is an area of growing interest in CAR-T manufacturing, particularly in the development of allo­geneic therapies. Targeted gene editing allows for the precise removal of genes that elicit an immunosuppressive response in the host. An allogeneic anti-CD19 CAR-T generated with CRISPR from Caribou Biosciences is currently in a Phase I clinical trial for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma (NCT04637763) [99, 100].
Lentiviral transduction and TALENs have been combined to develop a therapy for pediatric refractory relapsed B-cell acute lymphoblastic leukemia. The lentivirus was used to introduce the CAR, and TALENs were used to edit the native TCR and CD52 gene loci to generate an allogeneic product that achieved remission ahead of stem cell transplantation in 2 infants [101].
Treatment of solid tumors remains a key challenge for CAR-T therapies. Variations in CAR therapies, including CAR natural killer cells and CAR macro­phages, are under current clinical evaluation in solid tumor indications. Genetic engineering presents a potential solution regarding solid tumors. Genetic engineer­ing may allow for the ne-tuning of cells to overcome the hypoxic and immunosup­pressive microenvironment of solid tumors [53].
9 CAR-T Bioprocessing
Table 9.5 Strategies for optimizing production workows and quality attributes that may be affected
Production workow Strategies
Apheresis collection Collecting apheresis before treatment
with frontline chemotherapy or radiation regimens
Cell selection and expansion
Vector preparation and transduction
Formulation Selection of formulation buffers to
Infusion Cold chain temperature excursions
Dry thaw cryopreserved apheresis Reduction in human-derived media components Implement end-to-end, closed systems from cell selection to nal formulation
Media optimization Closed automated systems Quality control assays Plasmid design Filtration and purication
increase T-cell stemness Optimization of the cryopreservant type and concentration Container closure system integrity Container lling approaches (automated versus manual)
Thawing rate and type Hold time and infusion rate (in-use stability)
Quality attributes potentially affected
Purity, viability
Purity, sterility, viability
Viability Sterility, viability, potency Potency, efcacy High titer, transduction efciency High recovery, stability, potency,
Potency, cell count, transduction efciency Cell count, viability, potency Cell count, viability, sterility Cell count, viability, potency, transduction efciency, sterility
Viability, potency, transduction efciency Cell count, viability, potency Viability, potency, cell count (dose level)
251
The model of manufacturing for CAR-T therapies requires different demands than a traditional biopharmaceutical therapy. Because CAR-T manufacturing begins after a patient has fallen ill, the time from apheresis to drug product administration (“vein to vein” time) is critical to patient success. To this end, decentralized manu­facturing may present a manufacturing model that is more benecial to patients than centralized manufacturing. In decentralized manufacturing, a central hub can man­age multiple, smaller manufacturing facilities located closer to the patient and reduce the footprint of a complicated supply chain associated with centralized man­ufacturing [97]. Manufacturing at the point of care is another model for consider­ation. A collaboration between Lonza and CellPoint is exploring point of care manufacturing with Lonza’s Cocoon system for cell expansion, reducing vein to vein time to 5–7days [102]. As the eld continues to grow, decentralized manufac­turing may be key to expanding access to patients in new geographical areas and delivering medicines as quickly as possible.
As the CAR-T and immunotherapy eld continues to make exciting strides and new clinical offerings, manufacturing advancements are also growing to meet
252
A. Adeniran et al.
demands for scalability, price, and patient access. In this chapter, we have discussed current manufacturing processes for CAR-T therapies and key challenges and con­cerns for this growing eld. CAR-T cells hold great promise as a curative therapy, and as the knowledge of the therapy and eld grows, research scientists, manufac­turers, and clinical partners can continue to push the bounds of immunotherapy to offer more options for patients.
Acknowledgments The authors thank Dr. Alexandra McGregor for helpful discussions around potency assays.

References

1. Melenhorst JJ et al (2022) Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. Nature 602:503. https://doi.org/10.1038/s41586- 021- 04390- 6
2. Park JH etal (2018) Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med 378(5):449–459. https://doi.org/10.1056/nejmoa1709919
3. June CH, O’connor RS, Kawalekar OU, Ghassemi S, Milone MC (2018) CAR T cell immu­notherapy for human cancer. Science 359:1361
4. Zhang C, Liu J, Zhong JF, Zhang X (2017) Engineering CAR-T cells. Biomark Res 5(1) BioMed Central Ltd. https://doi.org/10.1186/s40364- 017- 0102- y
5. Levine BL, Miskin J, Wonnacott K, Keir C (2017) Global manufacturing of CAR T cell therapy. Mol Ther Methods Clin Dev 4:92. https://doi.org/10.1016/J.OMTM.2016.12.006
6. Tang QL, Gu LX, Xu Y, Liao XH, Zhou Y, Zhang TC (2021) Establishing functional len­tiviral vector production in a stirred bioreactor for CAR-T cell therapy. Bioengineered 12(1):2095–2105. https://doi.org/10.1080/21655979.2021.1931644
7. Bulcha JT, Wang Y, Ma H, Tai PWL, Gao G (2021) Viral vector platforms within the gene therapy landscape. Signal Transduct Target Ther 6(1):53. https://doi.org/10.1038/
s41392- 021- 00487- 6
8. Perry C, Rayat ACME (2021) Lentiviral vector bioprocessing. Viruses 13(2):268. https://doi.
org/10.3390/v13020268
9. Skrdlant LM, Armstrong RJ, Keidaisch BM, Lorente MF, DiGiusto DL (2018) Detection of replication competent lentivirus using a qPCR assay for VSV-G.Mol Ther Methods Clin Dev 8:1–7. https://doi.org/10.1016/j.omtm.2017.09.001
10. Schlimgen R et al (2016) Risks associated with lentiviral vector exposures and pre­vention strategies. J Occup Environ Med 58(12):1159–1166. https://doi.org/10.1097/
JOM.0000000000000879
11. Luis A (2020) The old and the new: prospects for non-integrating lentiviral vector technol­ogy. Viruses 12(10):1103. MDPI AG. https://doi.org/10.3390/v12101103
12. McCarron A, Donnelley M, McIntyre C, Parsons D (2016) Challenges of up-scaling lentivi­rus production and processing. J Biotech 240. Elsevier B.V:23–30. https://doi.org/10.1016/j.
jbiotec.2016.10.016
13. Chen A, Velickovic Z, Rasko J (2020) Vector copy number quality control testing for CAR T-cells: critical validation parameters. Cytotherapy 22(5):S142. https://doi.org/10.1016/j.
jcyt.2020.03.283
14. Rodrigues ME, Costa AR, Henriques M, Azeredo J, Oliveira R (2012) Wave characteriza­tion for mammalian cell culture: residence time distribution. New Biotechnol 29(3):402–408.
https://doi.org/10.1016/j.nbt.2011.10.006
9 CAR-T Bioprocessing
15. Comisel RM, Kara B, Fiesser FH, Farid SS (2021) Lentiviral vector bioprocess econom­ics for cell and gene therapy commercialization. Biochem Eng J 167:107868. https://doi.
org/10.1016/j.bej.2020.107868
16. Cattaneo, M, et al. (2020). Continuous perfusion with a stable producer HEK293 cell line for scaling up lentiviral vector production. Mol Ther 28(4):50
17. Roddie C, O’Reilly M, Pinto JDA, Vispute K, Lowdell M (2019) Manufacturing chime­ric antigen receptor T cells: issues and challenges. Cytotherapy 21(3):327–340. https://doi.
org/10.1016/j.jcyt.2018.11.009
18. Jarisch A etal (2020) Unstimulated apheresis for chimeric antigen receptor manufacturing in pediatric/adolescent acute lymphoblastic leukemia patients. J Clin Apher 35(5):398–405.
https://doi.org/10.1002/jca.21812
19. Terumo (2019) Principles of apheresis on the spectra optia. https://www.terumobct.com/
eLearning/306612715A- Principles- Of- Apheresis- CD/application/application.html?tracking =cd&gated=false
20. Fesnak AD (2020) The challenge of variability in chimeric antigen receptor T cell manufac­turing. Regen Eng Transl Med 6(3):322–329. https://doi.org/10.1007/s40883- 019- 00124- 3
21. Wang X etal (2021) Depletion of high-content CD14+ cells from apheresis products is criti­cal for successful transduction and expansion of CAR T cells during large-scale cGMP manu­facturing. Mol Ther Methods Clin Dev 22(September):377–387. https://doi.org/10.1016/j.
omtm.2021.06.014
22. Stroncek DF etal (2017) Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells. J Transl Med 15(1):4–11. https://doi.org/10.1186/s12967- 017- 1160- 5
23. Davis MM etal (2017) Predictors of manufacturing (MFG) success for chimeric antigen receptor (CAR) T cells in Non-Hodgkin Lymphoma (NHL). Cytotherapy 19(5):S118–S119.
https://doi.org/10.1016/j.jcyt.2017.02.190
24. Byrne J (2021) Kite: new data offers transparency into CAR T cell therapy manufactur­ing in real world setting. BioPharma-Reporter. https://www.biopharma- reporter.com/
Article/2021/04/07/Kite- New- data- offers- transparency- into- CAR- T- cell- therapy­manufacturing- in- real- world- setting. Accessed 26 Jan 2022
25. Tyagarajan S, Schmitt D, Acker C, Rutjens E (2019) Autologous cryopreserved leuka­pheresis cellular material for chimeric antigen receptor–T cell manufacture. Cytotherapy 21(12):1198–1205. https://doi.org/10.1016/j.jcyt.2019.10.005
26. Sommermeyer D et al (2016) Chimeric antigen receptor-modied T cells derived from dened CD8+ and. Leukemia 30(2):492–500. https://doi.org/10.1038/leu.2015.247.Chimeric
27. BMS (2022) Breyanzi package insert, June.
28. Kite Pharma (2002) Yescarta package insert, April
29. Novartis Pharmaceuticals (2022) Kymriah package insert, May
30. Kite Pharma (2021) Tecartus package insert
31. Celgene (2021) Abecma package insert
32. Jannsen Biotech (2022) Carvykti package insert, Feb
33. Stemcell (2020) Seamless integration into your changing awlessly integrate cell isolation into your evolving workow
34. Trickett A, Kwan YL (2003) T cell stimulation and expansion using anti-CD3/CD28 beads. J Immunol Methods 275(1–2):251–255. https://doi.org/10.1016/S0022- 1759(03)00010- 3
35. Poltorak MP etal (2020) Expamers: a new technology to control T cell activation. Sci Rep 10(1):17832. https://doi.org/10.1038/s41598- 020- 74595- 8
36. Thermo Fisher Scientic Inc (2017) First FDA-approved cell therapy for leukemia utilizes thermo sher scientic’s CTS Dynabeads technology. https://thermosher.
mediaroom.com/2017- 08- 30- First- FDA- Approved- Cell- Therapy- for- Leukemia- Utilizes­Thermo- Fisher- Scientics- CTS- Dynabeads- Technology#:~:text=The. Novartis chimeric
antigen receptor, therapy systems (CTS) portfolio
37. Castro A etal (2019) Protransduzin™– a novel transduction enhancer to accelerate en gros CAR-T production. Cytotherapy 21(5):e14. https://doi.org/10.1016/j.jcyt.2019.04.044
253
254
38. Zhang Z, Qiu S, Zhang X, Chen W (2018) Optimized DNA electroporation for primary human T cell engineering. BMC Biotechnol 18(1):1–9. https://doi.org/10.1186/s12896- 018- 0419- 0
39. Gattinoni L, Klebanoff CA, Restifo NP (2012) Paths to stemness: building the ultimate anti­tumour T cell. Nat Rev Cancer 12(10):671–684. https://doi.org/10.1038/nrc3322
40. Jin J, Cheng J, Huang M, Luo H, Zhou J (2020) Fueling chimeric antigen receptor T cells with cytokines. Am J Cancer Res 10(12):4038–4055
41. Alnabhan R, Gaballa A, Mörk L-M, Mattsson J, Uhlin M, Magalhaes I (2018) Media evaluation for production and expansion of anti-CD19 chimeric antigen receptor T cells. Cytotherapy 20(7):941–951. https://doi.org/10.1016/j.jcyt.2018.04.007
42. Tyagarajan S, Spencer T, Smith J (2020) Optimizing CAR-T cell manufacturing processes during pivotal clinical trials. Mol Ther Methods Clin Dev 16. Cell Press:136–144. https://doi.
org/10.1016/j.omtm.2019.11.018
43. Roberts ZJ, Better M, Bot A, Roberts MR, Ribas A (2018) Axicabtagene ciloleucel, a rst­in- class CAR T cell therapy for aggressive NHL.Leuk Lymphoma 59(8) Taylor and Francis Ltd:1785–1796. https://doi.org/10.1080/10428194.2017.1387905
44. Zhang W, Jordan KR, Schulte B, Purev E (2018) Characterization of clinical grade CD19 chimeric antigen receptor T cells produced using automated CliniMACS Prodigy system. Drug Des Devel Ther 12:3343–3356. https://doi.org/10.2147/DDDT.S175113
45. Ludwig J, Hirschel M (2020) Methods and process optimization for large-scale CAR T expansion using the G-Rex cell culture platform. In: Chimeric antigen receptor T cells: devel­opment and production, vol 2086. Humana Press, NewYork, pp165–177
46. ThermoFisher (2017) Nunc cell factory systems for consistent cell culture performance 2 the Thermo Scientic Nunc Cell Factory system difference
47. ThermoFisher (2019) CTS optmizer T cell expansion SFM, no phenol red, displays T cell manufacturing workow exibility
48. Hupfeld J, Heinrichs K, Kraft M, Tappe A (2020) Comparison of primary T cells cultured in static conditions versus rocking motion bioreactors. Cytotherapy 22(5):S147. https://doi.
org/10.1016/j.jcyt.2020.03.298
49. Hanley PJ, Lowdell MARK (2019) Advancing cellular therapies towards standard of care: a focus on testing of cellular therapy products. Cytotherapy 21(3):275–277. https://doi.
org/10.1016/j.jcyt.2019.02.003
50. Weil B, Hanley PJ, Lowdell M (2019) Proposal for the International Society for Cell & Gene Therapy position statement on assays for the quality control and potency assessment of adoptive cellular immunotherapies. Cytotherapy 21(3):367–375. https://doi.org/10.1016/j.
jcyt.2019.02.001
51. US FDA (2011) Potency tests for cellular and gene therapy products, vol 27. US FDA, pp568–577
52. Weems O, Sullivan D, Millard D (2021) CART cell potency assessment with 3D cancer spheroid models key
53. Kiesgen S, Messinger JC, Chintala NK, Tano Z, Adusumill PS (2021) Comparative analy­sis of assays to measure CAR T cell– mediated cytotoxicity. Nat Protoc 16(3):1331–1342.
https://doi.org/10.1038/s41596- 020- 00467- 0
54. Larson RC etal (2022) CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours. Nature 604:563–570. https://doi.org/10.1038/s41586- 022- 04585- 5
55. Li Y, Huo Y, Yu L, Wang J (2019) Quality control and nonclinical research on CAR-T cell products: general principles and key issues. Engineering 5(1):122–131. https://doi.
org/10.1016/j.eng.2018.12.003
56. Fda and Cber (2020) Testing of retroviral vector-based human gene therapy products for replication competent retrovirus during product manufacture and patient follow-up; Guidance for Industry [Online]. Available: https://www.fda.gov/vaccines- blood- biologics/
guidance- compliance-
A. Adeniran et al.
9 CAR-T Bioprocessing
57. White M, Whittaker R, Gándara C, Stoll EA (2017) A guide to approaching regulatory con­siderations for lentiviral-mediated gene therapies. Hum Gene Ther Methods 28(4) Mary Ann Liebert Inc:163–176. https://doi.org/10.1089/hgtb.2017.096
58. Hu Y, Huang J (2020) The chimeric antigen receptor detection toolkit. Front Immunol 11(August):1–16. https://doi.org/10.3389/mmu.2020.01770
59. Haderbache R etal (2021) Droplet digital PCR allows vector copy number assessment and monitoring of experimental CAR T cells in murine xenograft models or approved CD19 CAR T cell-treated patients. J Transl Med 19(1):1–13. https://doi.org/10.1186/s12967- 021- 02925- z
60. Lee SY etal (2018) Preclinical optimization of a CD20-specic chimeric antigen recep­tor vector and culture conditions. J Immunother 41(1):19. https://doi.org/10.1097/
CJI.0000000000000199
61. Gee AP (2018) GMP CAR-T cell production. Best Pract Res Clin Haematol 31(2):126–134.
https://doi.org/10.1016/J.BEHA.2018.01.002
62. Haastrup EK, Munthe-Fog L, Ballesteros OR, Fischer-Nielsen A, Svalgaard JD (2021) DMSO (Me2SO) concentrations of 1–2% in combination with pentaisomaltose are effective for cryopreservation of T cells. Transfus Apher Sci 60(4):103138. https://doi.org/10.1016/J.
TRANSCI.2021.103138
63. Windrum P, Morris TCM, Drake MB, Niederwieser D, Ruutu T (2005) Variation in dimethyl sulfoxide use in stem cell transplantation: a survey of EBMT centres. Bone Marrow Transplant 36(7):601–603. https://doi.org/10.1038/sj.bmt.1705100
64. Morgenstern DA etal (2016) Post-thaw viability of cryopreserved peripheral blood stem cells (PBSC) does not guarantee functional activity: important implications for quality assurance of stem cell transplant programmes. Br J Haematol 174(6):942–951. https://doi.org/10.1111/
BJH.14160
65. Anagnostakis I etal (2014) Successful short-term cryopreservation of volume-reduced cord blood units in a cryogenic mechanical freezer: effects on cell recovery, viability, and clono­genic potential. Transfusion (Paris) 54(1):211–223. https://doi.org/10.1111/TRF.12239
66. Germann A, Oh YJ, Schmidt T, Schön U, Zimmermann H, von Briesen H (2013) Temperature uctuations during deep temperature cryopreservation reduce PBMC recov­ery, viability and T-cell function. Cryobiology 67(2):193–200. https://doi.org/10.1016/J.
CRYOBIOL.2013.06.012
67. Dyson PG, Tocchetti R, Hiwase S (2014) Validation of an alternative transport system for cryopreserved haemopoietic progenitor cells. Cytotherapy 16(4):S56. https://doi.
org/10.1016/J.JCYT.2014.01.204
68. van der Walle CF, Godbert S, Saito G, Azhari Z (2021) Formulation considerations for autologous T cell drug products. Pharmaceutics 13(8):1317. https://doi.org/10.3390/
pharmaceutics13081317
69. Dasyam N, George P, Weinkove R (2020) Chimeric antigen receptor T-cell therapies: opti­mising the dose. Br J Clin Pharmacol 86(9):1678–1689. https://doi.org/10.1111/BCP.14281
70. Yan ZX et al (2019) Clinical efcacy and tumor microenvironment inu­ence in a dose-escalation study of anti-CD19 chimeric antigen recep­tor T cells in refractory B-cell non-Hodgkin’s lymphoma. Clin Cancer Res 25(23):6995–7003. https://doi.org/10.1158/1078- 0432.CCR- 19- 0101/74891/AM/
CLINICAL- EFFICACY- AND- TUMOR- MICROENVIRONMENT
71. Bu D etal (2021) Identication and development of PHE885: a novel and highly potent fully human anti-BCMA CAR-T manufactured with a novel T-charge TM platform for the treatment of multiple myeloma. Blood 138(Supplement 1):2770–2770. https://doi.
org/10.1182/BLOOD- 2021- 148390
72. Engels B etal (2021) Preservation of T-cell stemness with a novel expansionless CAR-T man­ufacturing process, which reduces manufacturing time to less than two days, drives enhanced CAR-T cell efcacy. Blood 138(Supplement 1):2848–2848. https://doi.org/10.1182/
BLOOD- 2021- 146246
255
256
73. Kishton RJ, Vodnala SK, Vizcardo R, Restifo NP (2022) Next generation immunotherapy: enhancing stemness of polyclonal T cells to improve anti-tumor activity. Curr Opin Immunol 74:39–45. https://doi.org/10.1016/J.COI.2021.10.001
74. Xia Y etal (2018) Treatment of metastatic non-small cell lung cancer with NY-ESO-1 specic TCR engineered-T cells in a phase I clinical trial: a case report. Oncol Lett 16(6):6998–7007. https://doi.org/10.3892/OL.2018.9534/HTML
75. Campbell A etal (2015) Concise review: process development considerations for cell ther­apy. Stem Cells Transl Med 4(10):1155–1163. https://doi.org/10.5966/SCTM.2014- 0294
76. Kaiser AD etal (2015) Towards a commercial process for the manufacture of genetically mod­ied T cells for therapy. Cancer Gene Ther 22(2):72–78. https://doi.org/10.1038/cgt.2014.78
77. Heathman TR, Nienow AW, McCall MJ, Coopman K, Kara B, Hewitt CJ (2015) The translation of cell-based therapies: clinical landscape and manufacturing challenges. Regen Med 10(1):49–64. https://doi.org/10.2217/RME.14.73/ASSET/IMAGES/LARGE/
FIGURE6.JPEG
78. Hourd P etal (2014) Qualication of academic facilities for small-scale automated manufac­ture of autologous cell-based products. Regen Med 9(6):799–815. https://doi.org/10.2217/
RME.14.47
79. Wang X, Rivière I (2016) Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol Ther Oncolytics 3:16015. https://doi.org/10.1038/MTO.2016.15
80. Jin J et al (2018) Enhanced clinical-scale manufacturing of TCR transduced T-cells using closed culture system modules. J Transl Med 16(1):1–13. https://doi.org/10.1186/
S12967- 018- 1384- Z/FIGURES/7
81. Vedvyas Y etal (2019) Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy. Sci Rep 9(1):1–15. https://doi.org/10.1038/
s41598- 019- 46938- 7
82. Marín Morales JM et al (2019) Automated clinical grade expansion of regula­tory T cells in a fully closed system. Front Immunol 10:38. https://doi.org/10.3389/
FIMMU.2019.00038/BIBTEX
83. Simmchen J, Ventura R, Segura J (2012) Progress in the removal of di-[2-Ethylhexyl]-phthal­ate as plasticizer in blood bags. Transfus Med Rev 26(1):27–37. https://doi.org/10.1016/J.
TMRV.2011.06.001
84. Wang K, Deng Q (2019) The thermal and mechanical properties of poly(ethylene-co-vinyl acetate) random copolymers (PEVA) and its covalently crosslinked analogues (cPEVA). Polymers 11(6):1055. https://doi.org/10.3390/POLYM11061055
85. Meneghel J, Kilbride P, Morris GJ (2020) Cryopreservation as a key element in the suc­cessful delivery of cell-based therapies—a review. Front Med 7:824. https://doi.org/10.3389/
FMED.2020.592242/BIBTEX
86. Papathanasiou MM, Stamatis C, Lakelin M, Farid S, Titchener-Hooker N, Shah N (2020) Autologous CAR T-cell therapies supply chain: challenges and opportunities? Cancer Gene Ther 27(10–11):799–809. https://doi.org/10.1038/s41417- 019- 0157- z
87. Lam C, Meinert E, Yang A, Cui Z (2021) Comparison between centralized and decentral­ized supply chains of autologous chimeric antigen receptor T-cell therapies: a UK case study based on discrete event simulation. Cytotherapy 23(5):433–451. https://doi.org/10.1016/J.
JCYT.2020.08.007
88. Graham C, Jozwik A, Pepper A, Benjamin R (2018) Allogeneic CAR-T cells: more than ease of access? Cells 7(10):155. https://doi.org/10.3390/cells7100155
89. Dai X, Mei Y, Cai D, Han W (2019) Standardizing CAR-T therapy: getting it scaled up. Biotechnol Adv 37(1):239–245. https://doi.org/10.1016/J.BIOTECHADV.2018.12.002
90. Elsallab M, Levine BL, Wayne AS, Abou-El-Enein M (2020) CAR T-cell product perfor­mance in haematological malignancies before and after marketing authorisation. Lancet Oncol 21(2) Elsevier:e104–e116. https://doi.org/10.1016/S1470- 2045(19)30729- 6
A. Adeniran et al.
9 CAR-T Bioprocessing
91. Karakostas P, Panoskaltsis N, Mantalaris A, Georgiadis MC (2020) Optimization of CAR T-cell therapies supply chains. Comput Chem Eng 139:106913. https://doi.org/10.1016/J.
COMPCHEMENG.2020.106913
92. Schultz L, Mackall C (2019) Driving CAR T cell translation forward. Sci Transl Med 11(481):2127. https://doi.org/10.1126/SCITRANSLMED.AAW2127/ASSET/3A6BC78D- 0
FDC- 4AC6- 89C9- C33D4A74498D/ASSETS/GRAPHIC/AAW2127- F1.JPEG
93. Novartis Pharmaceuticals (2020) Coding and billing guide for KYMRIAH ® (tisagenlecleu­cel), pp14–15
94. Pharma K (2017) Yescarta Hospital billing process, p80218
95. Pharma K (2009) Tecartus Hospital billing, pp3817–3817
96. Roy M (2021) Bristol Myers, bluebird bio set multiple myeloma therapy list price at $419,500. https://www.reuters.com/business/healthcare- pharmaceuticals/bluebird- bio- sets-
list- price- multiple- myeloma- therapy- 419500- 2021- 03- 29/. Accessed 8 Feb 2022
97. Abraham E, Trainor N, Ostrout N, Hewitt MM (2021) Cell therapy products are revolution­izing multiple therapeutic areas; to maintain this pace of innovation, manufacturing solutions must adapt. Curr Opin Biomed Eng 20:100340. https://doi.org/10.1016/j.cobme.2021.100340
98. Jenkins MJ, Farid SS (2018) Cost-effective bioprocess design for the manufacture of allo­geneic CAR-T cell therapies using a decisional tool with multi-attribute decision-making analysis. Biochem Eng J 137:192–204. https://doi.org/10.1016/j.bej.2018.05.014
99. ClinicalTrials.gov (2020) CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy for relapsed/refractory B Cell non-Hodgkin lymphoma. https://clinicaltrials.gov/ct2/show/
NCT04637763#wrapper
100. Caribou Biosciences (2021) Caribou biosciences announces dosing of rst patient in phase 1 clinical trial evaluating CB-010, a CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy. In: Patients with relapsed or refractory B cell non-Hodgkin lymphoma
101. Qasim W et al (2017) Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med 9(374):1–9. https://doi.org/10.1126/sci-
translmed.aaj2013
102. Clark M, Mateus M, Lempidaki S (2021) CellPoint and Lonza enter strategic collaboration to deliver CAR-T cells to patients at point-of-care
103. Sterner RM et al (2020) A graduate-level interdisciplinary curriculum in CAR-T cell therapy. Mayo Clin Proc Innov Qual Outcomes 4(2):203–210. https://doi.org/10.1016/J.
MAYOCPIQO.2019.12.006
104. Sterner RC, Sterner RM (2021) CAR-T cell therapy: current limitations and potential strate­gies. Blood Cancer J 11(4):1–11. https://doi.org/10.1038/s41408- 021- 00459- 7
105. di Stasi A etal (2011) Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 365(18):1673. https://doi.org/10.1056/NEJMOA1106152
106. Jones BS, Lamb LS, Goldman F, di Stasi A (2014) Improving the safety of cell therapy products by suicide gene transfer. Front Pharmacol 5:254. https://doi.org/10.3389/
FPHAR.2014.00254
257
Chapter 10
CRISPR Technology andIts Application inTherapeutics
RigelKishton, MontseMorell, KevinHolden, MeenakshiPrabhune, RebeccaRoberts, BobbyMoon, andRebeccaL.Nugent
Abstract Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)
technology is one of the most signicant scientic breakthroughs of this century, revolutionizing therapeutics. A component of bacterial immune systems, CRISPR has been repurposed to precisely edit DNA sequences. The accuracy, efciency, and simplicity of CRISPR technology have provided exciting new avenues to modify DNA and RNA for the treatment of human diseases. This includes both gene ther­apy, in which genes are edited invivo in patients, and gene-edited cell therapy, in which cells are edited exvivo and transfused into patients. This chapter is a compre­hensive guide to CRISPR gene editing and its applications in biotherapeutics. It begins with an introduction to CRISPR-Cas9 technology, examining its discovery and adaptation, mode of action, advantages over previous tools, derivatives of the original CRISPR-Cas9 technology, and gene editing methods. This is followed by a review of the applications of CRISPR technology in biotherapeutics, including both gene therapies and gene-edited cell therapies for the treatment of three disease cat­egories: genetic disorders, infectious diseases, and cancer. Relevant preclinical research and/or clinical trials are discussed for each disease category. The nal
R. Kishton Moonwalk Biosciences, South San Francisco, CA, USA e-mail: rigel.kishton@moonwalk.bio
M. Morell EditCo Bio, Redwood City, CA, USA e-mail: montse.morell@editco.bio
K. Holden · R. Roberts · B. Moon Synthego Corporation, Redwood City, CA, USA
M. Prabhune The Scientist, Lab X Media Group, Midland , ON, Canada e-mail: mprabhune@the-scientist.com
R. L. Nugent (*) Tessera Therapeutics, Sommerville, MA, USA e-mail: rnugent@tesseratx.com
K. Gadamasetti, S. A. Kolodziej (eds.), Bioprocessing, Bioengineering and Process Chemistry in the Biopharmaceutical Industry,
https://doi.org/10.1007/978-3-031-62007-2_10
259© The Author(s), under exclusive license to Springer Nature Switzerland AG 2024
Соседние файлы в папке Библиотека им академика М.И. Перельмана
Помощь Обратная связь Вопросы и предложения Пользовательское соглашение Политика конфиденциальности